Sarcopenia disease in Iran: an overview

  • Gita Shafiee
  • Ramin HeshmatEmail author
  • Afshin Ostovar
  • Iraj Nabipour
  • Bagher Larijani
Review article



Sarcopenia is a geriatric disease with adverse clinical outcomes, high rate of mortality and a major challenge to healthy elderly. This study aimed to undertake a survey to identify gaps and highlight strengths in sarcopenia research in order to progress research in this area for the next years in Iran.


This study included all studies published from the beginning until the first of 2019 in national and international journals by Iranian authors conducted in the field of sarcopenia. The databases including MEDLINE (via PubMed), Web of Science and SCOPUS were used as the sources of information. All relevant available academic studies, including review articles, original articles, case reports, conference abstracts, and letters were included in the analysis.


A total of 48 articles obtained and then categorized into six groups. These groups were; about Pathophysiology, Epidemiology of sarcopenia, Screening of sarcopenia, Nutrition, Physical activity and Association of Sarcopenia and Other Diseases that briefly findings of each study had been described. These findings showed that the prevalence of sarcopenia was 16.5% to 32.5%, using different definitions. A study developed and validated a screening model for identifying people with sarcopenia. Lifestyle changes such as diet can be appropriate strategies for the prevention of sarcopenia and also, physical activity is considered to be one of the few effective strategies to improve sarcopenia and prevent its outcomes, especially if in combination with appropriate nutritional supplementation. Sarcopenia is associated with adverse outcomes and other serious areas such as metabolic disorders, cancers, cardiovascular diseases, nephrology, gastroenterology, psychiatry, other geriatric diseases (such as osteoporosis, etc) and death. Some studies about these areas have been done in Iran.


By this study, we found that studies on sarcopenia, the gaps of sarcopenia research in Iran, and highlighted the research priorities for future works. The outcome of the present research is to ultimately improve the health, quality of life and well-being of sarcopenic people.


Sarcopenia Research Iran 


Compliance with ethical standards

Conflict of interest

The authors declared that they have no conflict of interest.


  1. 1.
    Cao L, Morley JE. Sarcopenia is recognized as an independent condition by an international classification of disease, tenth revision, clinical modification (ICD-10-CM) code. J Am Med Dir Assoc. 2016;17(8):675–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010;39(4):412–23.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian working Group for Sarcopenia. J Am Med Dir Assoc. 2014;15(2):95–101.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011;12(4):249–56.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Shafiee G, Ostovar A, Heshmat R, Keshtkar AA, Sharifi F, Shadman Z, et al. Appendicular skeletal muscle mass reference values and the peak muscle mass to identify sarcopenia among Iranian healthy population. Int J Prev Med 2018;9.Google Scholar
  6. 6.
    Leong DP, Teo KK, Rangarajan S, Kutty VR, Lanas F, Hui C, et al. Reference ranges of handgrip strength from 125,462 healthy adults in 21 countries: a prospective urban rural epidemiologic (PURE) study. J Cachexia Sarcopenia Muscle. 2016;7(5):535–46.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Hashemi R, Heshmat R, Motlagh AD, Payab M, Esmaillzadeh A, Baigy F, et al. Sarcopenia and its determinants among Iranian elderly (SARIR): Study protocol. J Diabetes Metab Disord. 2012;11(1).CrossRefGoogle Scholar
  8. 8.
    Hashemi R, Shafiee G, Motlagh AD, Pasalar P, Esmailzadeh A, Siassi F, et al. Sarcopenia and its associated factors in Iranian older individuals: results of SARIR study. Arch Gerontol Geriatr. 2016;66:18–22.PubMedCrossRefGoogle Scholar
  9. 9.
    Dorosty A, Arero G, Chamar M, Tavakoli S. Prevalence of sarcopenia and its association with socioeconomic status among the elderly in Tehran. Ethiop J Health Sci. 2016;26(4):389–96.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta-analysis of general population studies. J Diabetes Metab Disord 2017;16.Google Scholar
  11. 11.
    Shafiee G, Asgari Y, Soltani A, Larijani B, Heshmat R. Identification of candidate genes and proteins in aging skeletal muscle (sarcopenia) using gene expression and structural analysis. Peer J. 2018;6.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Bakhtiari N, Moslemee-Jalalvand E, Kazemi J. Ursolic acid: a versatile triterpenoid compound in regulating the aging. Physiology and Pharmacology. 2017;21(1):15–24.Google Scholar
  13. 13.
    Bakhtiari N. Isolation and optimization of mice skeletal muscle satellite cells using preplating method and culture media substitution. Physiology and Pharmacology. 2016;20(1):63–73.Google Scholar
  14. 14.
    Shafiee G, Heshmat R, Larijani B. Circulating cell-free nucleic acids as potential biomarkers for sarcopenia: a step toward personalized medicine. J Diabetes Metab Disord 2017;16.Google Scholar
  15. 15.
    Shafiee G, Ostovar A, Heshmat R, Darabi H, Sharifi F, Raeisi A, et al. Bushehr Elderly Health (BEH) programme: study protocol and design of musculoskeletal system and cognitive function (stage II). BMJ Open. 2017;7(8).PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Shafiee G, Heshmat R, Ostovar A, Keshtkar A, Nabipour I, Larijani B. Development and validation of sarcopenia screening model for older people: the bushehr elderly health program. Osteoporos Int. 2018;29:S329–S30.CrossRefGoogle Scholar
  17. 17.
    Beaudart C, Dawson A, Shaw SC, Harvey NC, Kanis JA, Binkley N, et al. Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteop Int : J Estab Result Coop Between Eur Foundation Osteop National Osteop Found USA. 2017;28(6):1817–33.CrossRefGoogle Scholar
  18. 18.
    Abiri B, Vafa M. Nutrition and sarcopenia: a review of the evidence of nutritional influences. Crit Rev Food Sci Nutr 2017:1–11.Google Scholar
  19. 19.
    Tsuboi M, Momosaki R, Vakili M, Abo M. Nutritional supplementation for activities of daily living and functional ability of older people in residential facilities: a systematic review. Geriatr Gerontol Int. 2018;18(2):197–210.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Hashemi R, Motlagh AD, Heshmat R, Esmaillzadeh A, Payab M, Yousefinia M, et al. Diet and its relationship to sarcopenia in community dwelling Iranian elderly: a cross sectional study. Nutrition. 2015;31(1):97–104.PubMedCrossRefGoogle Scholar
  21. 21.
    Mohseni R, Aliakbar S, Abdollahi A, Yekaninejad MS, Maghbooli Z, Mirzaei K. Relationship between major dietary patterns and sarcopenia among menopausal women. Aging Clin Exp Res. 2017;29(6):1241–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Moslehi N, Vafa M, Sarrafzadeh J, Rahimi-Foroushani A. Does magnesium supplementation improve body composition and muscle strength in middle-aged overweight women? A double-blind, placebo-controlled, randomized clinical trial. Biol Trace Elem Res. 2013;153(1–3):111–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Mafi F, Biglari S, Afousi AG, Gaeini AA. Epicatechin supplementation and resistance training-induced improvement of muscle strength and circulatory levels of plasma Follistatin and Myostatin in Sarcopenic older adults. J Aging Phys Act 2018:1–27.Google Scholar
  24. 24.
    Bakhtiari N, Hosseinkhani S, Tashakor A, Hemmati R. Ursolic acid ameliorates aging-metabolic phenotype through promoting of skeletal muscle rejuvenation. Med Hypotheses. 2015;85(1):1–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Heshmat R, Shafiee G, Ostovar A, Sharifi F, Nabipour I, Larjani B. Socioeconomic inequality of sarcopenia in iran: bushehr elderly health program. Osteoporos Int. 2018;29:S332.Google Scholar
  26. 26.
    Dassie GA, Motlagh AD, Chamari M, Mohammadreza E. Prevalence of food insecurity and its association with muscle mass, hand grip strength and gait speed among elderly in tehran. Int J Pharm Sci Res. 2016;7(7):2889–95.Google Scholar
  27. 27.
    Larijani B, Shafiee G, Shadman Z, Ostovar A, Heshmat R, Taheri E, et al. Association between nutritional status and sarcopenia in a community dwelling older population: The Bushehr Elderly Health (BEH) Program. J Bone Miner Res. 2018;33:439.Google Scholar
  28. 28.
    Vafa MR. Vitamin D and Sarcopenia. Adv Obes, Weight Manag Contrl. 2017;6(3):00155.Google Scholar
  29. 29.
    Ziaaldini MM, Marzetti E, Picca A, Murlasits Z. Biochemical pathways of sarcopenia and their modulation by physical exercise: a narrative review. Front Med 2017;4.Google Scholar
  30. 30.
    Negaresh R, Ranjbar R, Gharibvand MM, Habibi A, Mokhtarzade M. Effect of 8-week resistance training on hypertrophy, strength, & Myostatin concentration in old and young men. Salmand. 2017;12(1):56–66.CrossRefGoogle Scholar
  31. 31.
    Nourshahi M, Hedayati M, Gholamali M. Relationship between plasma myostatin with muscular volume and muscular maximal strength and it's response to acute resistance exercise in the elderly. Koomesh. 2013;15(1):102–9.Google Scholar
  32. 32.
    Pormozafari ZSAM, Nikooie R. The effect of 8-week resistance training and Leucine supplementation on protein synthesis among elderly men with sarcopenia. Int J Basic Sci Med. 2018;3(2):83–8.CrossRefGoogle Scholar
  33. 33.
    Hossein-Nezhad A, Yarjoo B, Niketeghad G, Bakhshizadeh A, Machawe M, Eshaghi SM, et al. Cyclic yoga for the prevention of age-related sarcopenia. Osteoporos Int. 2016;27:S283.CrossRefGoogle Scholar
  34. 34.
    Mansouri MRM, Haghighi AH, Askari R. Exercises of lumbar stabilizer muscles, resistance training, and soy food consumption: a comparative study between old and young women. Salmand. 2017;12(1):44–55.Google Scholar
  35. 35.
    Bahreinipour MA, Joukar S, Hovanloo F, Najafipour H, Naderi V, Rajiamirhasani A, et al. Mild aerobic training with blood flow restriction increases the hypertrophy index and MuSK in both slow and fast muscles of old rats: role of PGC-1 alpha. Life Sci. 2018;202:103–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Pour MAB, Joukar S, Hovanloo F, Najafipour H. Long-term low-intensity endurance exercise along with blood-flow restriction improves muscle mass and neuromuscular junction compartments in old rats. Iran J Med Sci. 2017;42(6):569–76.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Najafi Z, Kooshyar H, Mazloom R, Azhari A. The effect of fun physical activities on sarcopenia progression among elderly residents in nursing homes: a randomized controlled trial. J Caring Sci. 2018;7(3):137–42 Epub 2018/10/05.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Shafiee G, Heshmat R, Ostovar A, Sharifi F, Razi F, Nabipour I, et al. Association of sarcopenia and its parameters with type 2 diabetes: the bushehr elderly health program. Osteoporos Int. 2018;29:S328–S9.Google Scholar
  39. 39.
    Heshmat R, Shafiee G, Ostovar A, Sharifi F, Razi F, Nabipour I, et al. Association between metabolic syndrome and muscle health, quality and quantity of bone: the bushehr elderly health program. Osteoporos Int. 2018;29:S333.Google Scholar
  40. 40.
    Ayubi E, Safiri S. Prognostic value of computed tomography: measured parameters of body composition in primary operable gastrointestinal cancers: Methodologic issues. Ann Surg Oncol. 2017;24:628–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Sharifi F, Shafiee G, Heshmat R, Nabipour I, Larijani B, Arzaghi SM, et al. Association of cognitive impairment and sacopenia in older adults: bushehr elderly health project. Osteoporos Int. 2018;29:S483.Google Scholar
  42. 42.
    Larijani B, Shafiee G, Ostovar A, Heshmat R, Sharifi F, Nabipour I. Association of osteosarcopenia and cognitive impairment in a community dwelling older population: The Bushehr Elderly Health (BEH) program. J Bone Miner Res. 2018;33:313.Google Scholar
  43. 43.
    Khamseh ME, Malek M, Aghili R, Emami Z. Sarcopenia and diabetes: pathogenesis and consequences. British J Diab Vasc Disease. 2011;11(5):230–4.CrossRefGoogle Scholar
  44. 44.
    Aghili R, Malek M, Valojerdi AE, Banazadeh Z, Najafi L, Khamseh ME. Body composition in adults with newly diagnosed type 2 diabetes: Effects of metformin. J Diabetes Metab Disord. 2014;13(1).Google Scholar
  45. 45.
    Tabibi H, As'habi A, Najafi I, Hedayati M. Prevalence of dynapenic obesity and sarcopenic obesity and their associations with cardiovascular disease risk factors in peritoneal dialysis patients. Kidney research and clinical practice. 2018;37(4):404–13.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    As'habi A, Najafi I, Tabibi H, Hedayati M. Prevalence of sarcopenia and Dynapenia and their determinants in Iranian peritoneal Dialysis patients. Iran J Kidney Dis. 2018;12(1):53–60.PubMedGoogle Scholar
  47. 47.
    Heshmat R, Shafiee G, Ostovar A, Sharifi F, Razi F, Nabipour I, et al. Association of OSTEOSARCOPENIA with CARDIOMETABOLIC risk factors in older people: BUSHEHR elderly health program. Osteoporos Int. 2018;29:S332–S3.Google Scholar
  48. 48.
    Shafiee G, Heshmat R, Ostovar A, Sharifi F, Nabipour I, Larijani B. Association of sarcopenia components and bone parameters with risk of falling in older people: the bushehr elderly health program. Osteoporos Int. 2018;29:S328.Google Scholar
  49. 49.
    Hajahmadi M, Shemshadi S, Khalilipur E, Amin A, Taghavi S, Maleki M, et al. Muscle wasting in young patients with dilated cardiomyopathy. J Caxhexia Sarcopenia Muscle. 2017;8(4):542–8.CrossRefGoogle Scholar
  50. 50.
    Penson PE, Mancini GBJ, Toth PP, Martin SS, Watts GF, Sahebkar A, et al. Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. J Cachexia Sarcopenia Muscle. 2018;9(6):1023–33.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Bielecka-Dabrowa A, Fabis J, Mikhailidis DP, von Haehling S, Sahebkar A, Rysz J, et al. Prosarcopenic effects of statins may limit their effectiveness in patients with heart failure. Trends Pharmacol Sci. 2018;39(4):331–53.PubMedCrossRefGoogle Scholar
  52. 52.
    Sahebkar A, Saboni N, Pirro M, Banach M. Curcumin: an effective adjunct in patients with statin-associated muscle symptoms? Journal of Cachexia. Sarcopenia and Muscle. 2017;8(1):19–24.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Gita Shafiee
    • 1
  • Ramin Heshmat
    • 1
    Email author
  • Afshin Ostovar
    • 2
  • Iraj Nabipour
    • 3
  • Bagher Larijani
    • 4
  1. 1.Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences InstituteTehran University of Medical SciencesTehranIran
  2. 2.Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences InstituteTehran University of Medical SciencesTehranIran
  3. 3.The Persian Gulf Tropical Medicine Research CenterBushehr University of Medical SciencesBushehrIran
  4. 4.Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences InstituteTehran University of Medical SciencesTehranIran

Personalised recommendations